Published in Medical Letter on the CDC and FDA, December 3rd, 2006
The MedClose VCS (vascular closure device) as a nonsignificant, low risk device determined by both a U.S. independent review board and a Canadian independent review board with subsequent approval by the Canadian Health, Health Products and Food Branch, Therapeutic Products Division for Protocol #CL-7000, is intended to seal femoral arterial puncture sites and reduce time to hemostasis and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.